Is Supriya Lifescience a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Supriya Lifescience Ltd is a average quality company .

Is Supriya Lifescience undervalued or overvalued?

The key valuation ratios of Supriya Lifescience Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Supriya Lifescience share price return in the past 10 years?

Data is not available for this company

Is Supriya Lifescience a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Supriya Lifescience Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

Supriya Lifescience Ltd - Stock Valuation and Financial Performance

Name: Supriya Lifescience
Brand: Supriya Lifescience

BSE: 543434 | NSE: SUPRIYA | Pharmaceuticals & Drugs | Small Cap

Place order

Supriya Lifescience Share Price

₹704.15 15.00 2.18%
as on 21-Nov'24 16:59

10 Year X-Ray of Supriya Lifescience:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	15.8%	12.3%	11.5%	13.8%	36.5%	49.7%	60.1%	43.3%	18.7%	22.3%	-
Value Creation Index ⓘ	0.2	-0.1	-0.2	0.0	1.7	2.7	3.5	2.1	0.3	0.6	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	138	171	184	213	278	312	391	530	461	570	625
Sales YoY Gr.	-	23.8%	7.5%	16%	30.5%	12.2%	25.5%	35.5%	-13%	23.7%	-
Adj EPS ⓘ	1.1	0.8	0.7	0.9	5.3	10.1	16.9	18.9	11.2	14.8	19.6
YoY Gr.	-	-22.9%	-19.1%	26.5%	520.9%	88.6%	67.7%	11.7%	-40.8%	32.5%	-
BVPS (₹) ⓘ	4.3	4.8	5.5	7.5	12.8	20.4	36.7	76.5	86.9	101.3	112.6
Adj Net Profit ⓘ	8	6.2	5	6.3	39.1	73.7	124	152	89.9	119	158
Cash Flow from Ops. ⓘ	-6.3	13.5	27.3	27.8	48.9	116	75.9	48.8	63.6	113	-
Debt/CF from Ops. ⓘ	-15.8	9.6	5.1	4.7	1.8	0.7	0.9	0.4	0.3	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	17.1%	15.5%	13.4%	23.7%
Adj EPS ⓘ	33.6%	22.6%	-4.3%	32.5%
BVPSⓘ	42.1%	51.2%	40.3%	16.6%
Share Price	-	-	-	186.8%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	23.6	15.6	11.3	12.5	52.6	60.7	59.2	34.3	13.7	15.7	18.3
Op. Profit Mgn % ⓘ	12.5	11.9	9.3	10.3	23.8	31.7	44.3	40.4	27.9	30.8	35.9
Net Profit Mgn % ⓘ	5.8	3.6	2.7	3	14.1	23.7	31.6	28.6	19.5	20.9	25.2
Debt to Equity ⓘ	3.2	3.7	3.5	2.4	1	0.6	0.3	0	0	0	0
Working Cap Days ⓘ	211	217	220	174	141	166	158	140	206	179	113
Cash Conv. Cycle ⓘ	65	70	65	54	26	22	19	51	82	53	91

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 13.39%

Sales growth is good in last 4 quarters at 21.16%

Return on Equity has declined versus last 3 years average to 18.30%

Net Profit has been subdued in last 3 years -4.31%

Latest Financials - Supriya Lifescience Ltd.

	Standalone	Consolidated
TTM EPS (₹)	19.6	-
TTM Sales (₹ Cr.)	625	-
BVPS (₹.) ⓘ	112.6	-
Reserves (₹ Cr.) ⓘ	890	-
P/BV ⓘ	6.12	-
PE ⓘ	35.21	-

From the Market
52 Week Low / High (₹)	240.10 / 704.35
All Time Low / High (₹)	170.05 / 689.65
Market Cap (₹ Cr.)	5,546
Equity (₹ Cr.)	16.1
Face Value (₹)	2
Industry PE ⓘ	43

Management X-Ray of Supriya Lifescience:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Supriya Lifescience

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Supriya Lifescience

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	138	171	184	213	278	312	391	530	461	570
Operating Expenses ⓘ	121	151	166	191	213	213	218	316	332	395
Manufacturing Costs	9	12	16	21	27	24	23	34	50	55
Material Costs	88	107	123	136	147	138	128	196	181	222
Employee Cost	9	10	13	16	19	26	33	49	56	68
Other Costs ⓘ	14	21	15	18	21	25	34	37	46	50
Operating Profit ⓘ	17	20	17	22	64	98	173	214	128	176
Operating Profit Margin (%)	12.4%	11.5%	9.3%	10.3%	23.2%	31.6%	44.3%	40.4%	27.9%	30.8%
Other Income ⓘ	2	2	7	9	8	11	5	8	10	11
Interest ⓘ	7	10	12	11	10	7	4	4	3	5
Depreciation ⓘ	2	4	5	5	5	6	7	10	12	16
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	10	8	8	14	57	96	167	207	123	166
Tax ⓘ	2	2	2	6	18	23	44	55	34	47
Profit After Tax	8	6	6	9	39	73	124	152	90	119
PAT Margin (%)	6.0%	3.3%	3.1%	4.1%	14.2%	23.6%	31.6%	28.6%	19.5%	20.9%
Adjusted EPS (₹)	1.1	0.8	0.8	1.2	5.4	10.0	16.9	18.9	11.2	14.8
Dividend Payout Ratio (%)	7%	26%	0%	0%	0%	20%	3%	3%	5%	5%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	37	41	46	55	94	149	269	616	699	815
Share Capital ⓘ	5	15	15	15	15	15	15	16	16	16
Reserves ⓘ	33	26	31	40	79	135	254	600	683	799
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	99	129	140	121	85	79	67	21	17	0
Long Term Debt	20	34	45	35	8	2	0	0	0	0
Short Term Debt	79	95	95	86	77	77	67	21	17	0
Trade Payables	30	50	41	42	44	49	51	49	64	60
Others Liabilities ⓘ	10	12	15	28	30	59	58	49	40	49
Total Liabilities ⓘ	176	231	241	245	253	336	445	735	820	924
Fixed Assets
Gross Block	71	89	98	96	95	114	123	223	306	371
Accumulated Depreciation	10	14	9	5	10	16	23	33	45	61
Net Fixed Assetsⓘ	61	75	89	91	85	98	100	190	262	310
CWIP ⓘ	11	25	36	34	35	40	79	43	68	149
Investmentsⓘ	0	0	0	0	0	0	0	0	25	64
Inventories	39	53	38	32	31	49	72	92	116	85
Trade Receivables	35	42	50	53	60	52	74	115	85	112
Cash Equivalents	5	7	6	3	2	2	89	228	158	75
Others Assetsⓘ	24	28	23	32	41	95	31	66	108	129
Total Assets ⓘ	176	231	241	245	253	336	445	735	820	924

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	-6	14	27	28	49	116	76	49	64	113
PBT ⓘ	10	8	8	14	57	96	167	207	123	166
Adjustment ⓘ	9	13	16	16	13	10	5	7	5	2
Changes in Working Capital ⓘ	-25	-7	3	1	-7	37	-67	-104	-34	-17
Tax Paid ⓘ	0	0	0	-3	-14	-27	-30	-61	-31	-38
Cash Flow From Investing Activity ⓘ	-23	-33	-27	-5	5	-25	-47	-60	-124	-174
Capex	-17	-18	-10	-5	5	-25	-47	-60	-108	-146
Net Investments	0	0	0	0	0	0	0	0	-25	-39
Others ⓘ	-6	-15	-17	0	0	0	0	0	9	11
Cash Flow From Financing Activityⓘ	30	21	-2	-20	-50	-29	-15	150	-10	-22
Net Proceeds from Shares ⓘ	0	1	-1	0	0	0	0	200	0	0
Net Proceeds from Borrowing ⓘ	5	15	0	-9	-27	-6	-2	0	0	0
Interest Paid ⓘ	-7	-10	-13	-11	-10	-6	-4	-4	0	-1
Dividend Paid ⓘ	0	0	0	0	0	-18	-4	-4	-5	-5
Others ⓘ	32	16	12	-1	-13	0	-4	-42	-5	-17
Net Cash Flow ⓘ	1	2	-2	3	4	62	15	139	-70	-83

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	29.61	17.2	15.05	18.38	53.11	60.42	59.17	34.34	13.66	15.73
ROCE (%)	15.83	12.27	11.48	13.8	36.52	49.67	60.12	43.34	18.71	22.31
Asset Turnover Ratio	0.98	0.92	0.83	0.98	1.29	1.22	1.1	1	0.66	0.74
PAT to CFO Conversion(x)	-0.75	2.33	4.5	3.11	1.26	1.59	0.61	0.32	0.71	0.95
Working Capital Days
Receivable Days	77	76	86	78	64	57	53	59	71	55
Inventory Days	84	90	85	53	35	41	52	51	74	57
Payable Days	126	135	134	111	107	123	143	93	114	102

Supriya Lifescience Ltd Stock News

Supriya Lifescience Ltd FAQs

What is the share price of Supriya Lifescience?

Company share prices are keep on changing according to the market conditions. The closing price of Supriya Lifescience on 21-Nov-2024 16:59 is ₹704.1.

What is the market cap of Supriya Lifescience?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Nov-2024 16:59 the market cap of Supriya Lifescience stood at ₹5,546.5.

What is the P/E ratio of Supriya Lifescience?

The latest P/E ratio of Supriya Lifescience as of 21-Nov-2024 16:59 is 35.21.

What is the P/B ratio of Supriya Lifescience?

The latest P/B ratio of Supriya Lifescience as of 21-Nov-2024 16:59 is 6.12.

What is the 52-week high and low of Supriya Lifescience?

The 52-week high of Supriya Lifescience is ₹704.4 and the 52-week low is ₹240.1.

What is the TTM revenue of Supriya Lifescience?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Supriya Lifescience is ₹625.0 ( Cr.) .

About Supriya Lifescience Ltd

The company was incorporated as ‘Supriya Lifescience Limited’ pursuant to a certificate of incorporation dated March 26, 2008 issued by the Registrar of Companies, Maharashtra at Mumbai (RoC), upon the conversion of ‘M/s Supriya Chemicals’, a partnership firm, into a public limited company, in accordance with the provisions of Part IX of the Companies Act, 1956. The company commenced operations pursuant to a certificate for commencement of business dated April 1, 2008 issued by RoC.

The company is a global leading manufacturer of Active pharmaceutical Ingredients. The company’s pharmaceutical business is organized into domestic and export sales, according to the geographies in which it operates. It has grown its API business in several countries across Europe, Latin America, Asia (excluding India), North America and India. The company’s customers include global pharma companies such as Syntec Do Brasil LTDA, American International Chemical Inc and AT Planejamento E Desenbolvimento De Negocios Ltda, with whom it has business relationship for over nine years, and Suan Farma Inc, Acme Generics LLP, Akum Drugs Ltd and Mankind Pharma Ltd with whom it has business relationship for over four years. Its products are registered with various international regulatory authorities such as USFDA, EDQM, NMPA (previously known as SFDA), KFDA, PMDA, TGA and Taiwan FDA.

Business area of the company

The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development. The company has niche product offerings of various APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic.

Awards, accreditations or recognitions

2009: Certificate of Excellence for outstanding Export Performance in the product group Chemicals, Drugs, Pharma and Allied Products (MSME) awarded by Federation of Indian Export Organisations.
2010: Special Recognition National Award for Research and Development awarded by Ministry of Micro Small and Medium Enterprises, Government of India.
2016: Export House for the Year for 2015-16 awarded by Directorate of Industries, Government of Maharashtra.
2016: Export Achievement for 2015-16 in the product group Basic Chemical, Pharmaceutical & Cosmetics Products (MSME) awarded by Directorate of Industries, Government of Maharashtra.
2017: Export House for the Year for 2016-17 awarded by Directorate of Industries, Government of Maharashtra
2017: Export Achievement for 2016-17 in the product group Basic Chemical & Pharmaceutical Cosmetics (SSI) awarded by Directorate of Industries, Government of Maharashtra.
2019: Outstanding Export Performance Award for the year 2018-19 for product group API / Bulk Drugs by Pharmaceuticals Export Promotion Council of India.

Major events and milestones

2008 Incorporation of the Company upon its conversion from a partnership firm to a public limited company.
2009: Started production of Ketamine Hydrochloride.
2010: CEP (Certificate of Sustainability) granted for Chlorphenamine Maleate.
2011: IDL granted for Chlorphenamine Maleate.
2013: COFEPRIS and KFDA approval granted.
2014: USFDA approval granted
2014: IDL granted for Brompheniramine Maleate.
2015: EUGMP and EDQM approval granted.
2017: CEP (Certificate of Sustainability) granted for Pheniramine Maleate.
2017: Second time USFDA approval granted.
2018: CEP (Certificate of Sustainability) granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride.
2020: Third time USFDA approval.
2021: CEP (Certificate of Suitability) granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate.
2021: NMPA approval granted.
2021: Health Canada approval.